Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Abstract

Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (Funded by F. Hoffmann-La Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472 .).

Keywords

Affiliated Institutions

• Institut de Recherche en Cancérologie de Montpellier FR
• Mammazentrum Hamburg DE
• University Hospital Heidelberg DE
• Krankenhaus Jerusalem DE
• Ospedale Papa Giovanni XXIII IT
• Orlando Health US
• Yale University US
• UF Health Cancer Center
• German Breast group DE
• Yale Cancer Center US
• Virginia Commonwealth University US
• Helios Hospital Berlin-Buch DE
• NSABP Foundation US
• University of Florida Health Science Center US
• Université de Montpellier FR
• Instituto Nacional de Cancerología MX
• Instituto do Câncer do Estado de São Paulo BR
• UPMC Hillman Cancer Center US
• Evangelische Kliniken Gelsenkirchen DE
• Providence Portland Medical Center US
• Smilow Cancer Hospital US
• German Cancer Research Center DE
• Universitätsklinikum Erlangen DE
• Cancer Trials Ireland IE
• Roche (United Kingdom) GB
• Inserm FR
• Hospital Universitario La Paz ES
• Fudan University Shanghai Cancer Center CN
• Stanford University US
• Cardiovascular Center Bethanien DE
• Sana Klinikum Offenbach DE
• National Center for Tumor Diseases DE
• Comprehensive Cancer Center Erlangen DE
• University of Florida Health US
• Heidelberg University DE
• Allegheny Health Network US
• National Taiwan University Hospital TW

Related Publications